Giá hiện tại
Giá mục tiêu
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. The company is headquartered in Jupi...|
e.g. Promoter holding
Loading chart...
Dự báo EPS và doanh thu theo đồng thuận của các nhà phân tích.
| Metric (B) | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 |
|---|---|---|---|---|---|
| $-0.08 | $-0.26 | $-0.05 | $0.06 | $0.06 | |
| 0 | 0 | 0 | 0.01 | 0.01 | |
| -14.3% | -4.0% | -25.0% | -45.5% | -45.5% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NNeuroSense... | NRSN | $3.21M | — | 2.64 | — | — | -2,175.00% | — |
| 2. | RReviva Pha... | RVPHW | $85.81M | — | — | — | — | -916.00% | — |
| 3. | BBioCardia... | BCDA | $12.58M | — | 15.07 | — | — | -1,803.00% | -100.00% |
| 4. | OOS Therapi... | OSTX | $34.87M | — | 12.74 | — | — | -914.00% | — |
| 5. | OOS Therapi... | OSTX | $34.87M | — | 12.74 | — | — | -914.00% | — |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Quarter (M) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.02 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 |
Gross Profit % | - | - | - | - | - | - | 100% | 86.88% |
| 0.49 | 1.46 | 1.54 | 2.26 | 2.3 | 2.83 | 2.83 | 2.76 | |
EBIT | -0.49 | -1.46 | -1.54 | -2.26 | -2.3 | -2.81 | -2.81 | -2.74 |
OPM % | - | - | - | - | - | -12886.7% | -12886.7% | -11313.45% |
Non-Operating Income | -0.1 | -0.07 | 0.01 | 0.01 | 0.01 | 0.23 | 0.23 | 0.47 |
PBT | -0.59 | -1.53 | -1.53 | -2.25 | -2.29 | -2.58 | -2.58 | -2.27 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -0.59 | -1.53 | -1.53 | -2.25 | -2.29 | -2.58 | -2.58 | -2.27 |
NPM % | - | - | - | - | - | -11814.24% | -11814.24% | -9380.89% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
Revenue | 0 | 1.13 | 0.64 | 0.23 | 0 | 0 | 0.02 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1.13 | 0.64 | 0.23 | 0 | 0 | 0.02 |
Gross Profit % | - | 100% | 100% | 100% | - | - | 80.59% |
| 2.18 | 2.98 | 4.55 | 3.67 | 3.87 | 3.09 | 8.93 | |
EBIT | -2.18 | -1.85 | -3.91 | -3.43 | -3.87 | -3.09 | -8.91 |
OPM % | - | -164.41% | -612.36% | -1471.38% | - | - | -40873.19% |
Non-Operating Income | 0 | 0.2 | -0.29 | -1.53 | -0.91 | 0.65 | 0.26 |
PBT | -3.05 | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 | -8.64 |
Income Tax | 0 | 0 | 0.18 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | -4.27% | - | - | - | - |
Net Income | -3.05 | -1.65 | -4.38 | -4.96 | -4.78 | -2.44 | -8.64 |
NPM % | - | -146.92% | -686.39% | -2125.15% | - | - | -39662.77% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0.21 | 0.33 | 0.06 | 0.03 | 3.77 | 3.79 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0.34 | 0.12 | 0.01 | 0 | 0.88 | 1.04 | |
| 0 | 0 | 0.21 | 0.17 | 0.12 | 1.55 | 0.74 | |
Total Assets | 0.01 | 0.55 | 0.67 | 0.24 | 0.15 | 6.2 | 5.56 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| -5.02 | -3.71 | -5.18 | -7.15 | -5.8 | 4.17 | -1.84 | |
| 1.21 | 0.11 | 0.65 | 1.9 | 2.25 | 0.22 | 5.32 | |
| 3.81 | 4.15 | 5.19 | 5.48 | 3.7 | 1.81 | 2.21 | |
| 0 | 0 | 0 | 0 | -0 | 0 | -0.13 | |
Total Liabilities | 0.01 | 0.55 | 0.67 | 0.24 | 0.15 | 6.2 | 5.56 |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| -0.14 | -0.25 | -1.74 | -1.25 | -0.48 | -3.91 | -5.41 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0.11 | 0.46 | 1.86 | 0.98 | 0.45 | 7.65 | 5.43 | |
Net CFNet Cash Flow | -0.04 | 0.21 | 0.12 | -0.27 | -0.04 | 3.74 | 0.02 |
FCFFree Cash Flow | -0.14 | -0.25 | -1.74 | -1.25 | -0.48 | -3.91 | -5.41 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| - | 37.9% | 98.5% | 80.5% | 73.9% | 299.5% | -738.8% | |
| -0.24 | -0.03 | -0.13 | -0.27 | -0.39 | 0.05 | -2.90 | |
| 0.00 | 0.13 | 0.08 | 0.01 | 0.00 | 2.31 | 0.65 | |
| - | 4.05 | 1.05 | 0.52 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | 0.05 | 0.15 | 0.40 | 0.25 | 0.10 | 1.60 | 0.63 |
Payout Ratio | - | - | - | - | - | - | - |
| - | - | -43.3% | -63.4% | -100.0% | - | - | |
| - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | |
| 3.00 | 4.00 | 2.00 | 3.00 | 1.00 | 3.00 | 3.00 | |
| - | - | -22.66 | -77.16 | - | - | - | |
| - | 100.00 | 100.00 | 100.00 | - | 50.00 | 100.00 | |
| - | -1.5% | -6.9% | -21.3% | - | - | -396.6% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Ai sở hữu Jupiter Neurosciences Inc, theo hồ sơ SEC
Chưa có hồ sơ sở hữu SEC cho công ty này.
Hồ sơ SEC và bản ghi cuộc gọi kết quả kinh doanh của Jupiter Neurosciences Inc
Chưa có hồ sơ SEC cho công ty này.
What recent news says about Jupiter Neurosciences Inc, scored for sentiment.